Search Results - Balasubramaniam, Sanjeeve

Association between Benign Thyroid and Endocrine Disorders and Subsequent Risk of Thyroid Cancer among 4.5 Million U.S. Male Veterans by Balasubramaniam, Sanjeeve, Ron, Elaine, Gridley, Gloria, Schneider, Arthur B., Brenner, Alina V.

Get full text Get full text Get full text

Targeting the Epigenome in Lung Cancer: Expanding Approaches to Epigenetic Therapy by Jakopovic, Marko, Thomas, Anish, Balasubramaniam, Sanjeeve, Schrump, David, Giaccone, Giuseppe, Bates, Susan E.

Get full text Get full text Get full text

Advancing Clinical Trials to Streamline Drug Development by Bates, Susan E., Berry, Donald A., Balasubramaniam, Sanjeeve, Bailey, Stuart, Rubin, Eric H., LoRusso, Patricia M.

Get full text Get full text Get full text

Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer by Del Rivero, Jaydira, Edgerly, Maureen, Ward, Jean, Madan, Ravi A., Balasubramaniam, Sanjeeve, Fojo, Tito, Gramza, Ann W.

Get full text Get full text Get full text

Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma by Burotto, Mauricio, Edgerly, Maureen, Poruchynsky, Marianne, Velarde, Margarita, Wilkerson, Julia, Kotz, Herb, Bates, Susan, Balasubramaniam, Sanjeeve, Fojo, Tito

Get full text Get full text Get full text

A population pharmacokinetic/toxicity model for the reduction of platelets during a 48-h continuous intravenous infusion of the histone deacetylase inhibitor belinostat by Peer, Cody J., Hall, Oliver M., Sissung, Tristan M., Piekarz, Richard, Balasubramaniam, Sanjeeve, Bates, Susan E., Figg, William D.

Get full text Get full text Get full text

A Phase II Multi‐Center Study of Bevacizumab in Combination with Ixabepilone in Subjects with Advanced Renal Cell Carcinoma by Burotto, Mauricio, Edgerly, Maureen, Velarde, Margarita, Balasubramaniam, Sanjeeve, Drabkin, Harry, Gormaz, Juan G., O'Sullivan, Ciara, Madan, Ravi, Fojo, Tito

Get full text Get full text Get full text

The VEGF Inhibitor Axitinib Has Limited Effectiveness as a Therapy for Adrenocortical Cancer by O'Sullivan, Ciara, Edgerly, Maureen, Velarde, Margarita, Wilkerson, Julia, Venkatesan, Aradhana M., Pittaluga, Stefania, Yang, Sherry X., Nguyen, Dat, Balasubramaniam, Sanjeeve, Fojo, Tito

Get full text Get full text Get full text

Continued tumor reduction of metastatic pheochromocytoma/paraganglioma harboring succinate dehydrogenase subunit B mutations with cyclical chemotherapy by Jawed, Irfan, Velarde, Margarita, Därr, Roland, Wolf, Katherine I., Adams, Karen, Venkatesan, Aradhana M., Balasubramaniam, Sanjeeve, Poruchynsky, Marianne S., Reynolds, James C., Pacak, Karel, Fojo, Tito

Get full text Get full text Get full text

UGT1A1 Genotype-Dependent Dose Adjustment of Belinostat in Patients With Advanced Cancers Using Population Pharmacokinetic Modeling and Simulation by Peer, Cody J., Goey, Andrew K. L., Sissung, Tristan M., Erlich, Sheryl, Lee, Min-Jung, Tomita, Yusuke, Trepel, Jane B., Piekarz, Richard, Balasubramaniam, Sanjeeve, Bates, Susan E., Figg, William D.

Get full text Get full text Get full text

Vaccine-Stimulated, Adoptively Transferred CD8(+) T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction by Palmer, Douglas C., Balasubramaniam, Sanjeeve, Hanada, Ken-ichi, Wrzesinski, Claudia, Yu, Zhiya, Farid, Shahram, Theoret, Marc R., Hwang, Leroy N., Klebanoff, Christopher A., Gattinoni, Luca, Goldstein, Allan L., Yang, James C., Restifo, Nicholas P.

Get full text Get full text

Effects of UGT1A1 Genotype on the Pharmacokinetics, Pharmacodynamics, and Toxicities of Belinostat Administered by 48-Hour Continuous Infusion in Patients With Cancer by Goey, Andrew K. L., Sissung, Tristan M., Peer, Cody J., Trepel, Jane B., Lee, Min-Jung, Tomita, Yusuke, Ehrlich, Sheryl, Bryla, Christine, Balasubramaniam, Sanjeeve, Piekarz, Richard, Steinberg, Seth M., Bates, Susan E., Figg, William D.

Get full text Get full text Get full text

Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lung by Balasubramaniam, Sanjeeve, Redon, Christophe E., Peer, Cody J., Bryla, Christine, Lee, Min-Jung, Trepel, Jane B., Tomita, Yusuke, Rajan, Arun, Giaccone, Giuseppe, Bonner, William M., Figg, William D., Fojo, Tito, Piekarz, Richard L., Bates, Susan E.

Get full text Get full text Get full text

An FDA Pooled Analysis of Patients with Melanoma Treated with an Anti-PD1 Antibody Beyond RECIST Progression by Beaver, Julia A., Hazarika, Maitreyee, Mulkey, Flora, Mushti, Sirisha, Chen, Huanyu, He, Kun, Sridhara, Rajeshwari, Goldberg, Kirsten B., Chuk, Meredith K., Chi, Dow-Chung, Chang, Jennie, Barone, Amy, Balasubramaniam, Sanjeeve, Blumenthal, Gideon M., Keegan, Patricia, Pazdur, Richard, Theoret, Marc R.

Get full text Get full text Get full text

FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer by Arora, Shaily, Balasubramaniam, Sanjeeve, Zhang, Hui, Berman, Tara, Narayan, Preeti, Suzman, Daniel, Bloomquist, Erik, Tang, Shenghui, Gong, Yutao, Sridhara, Rajeshwari, Turcu, Francisca Reyes, Chatterjee, Deb, Saritas‐Yildirim, Banu, Ghosh, Soma, Philip, Reena, Pathak, Anand, Gao, Jennifer J., Amiri‐Kordestani, Laleh, Pazdur, Richard, Beaver, Julia A.

Get full text Get full text Get full text